Dr. Doebele Discusses Brain Metastases in ROS1+ NSCLC

Robert C. Doebele, MD, PhD, associate professor, Division of Medical Oncology, University of Colorado, discusses brain metastases in ROS1-positive non—small cell lung cancer (NSCLC).

Crizotinib (Xalkori), the current standard of care, does not have good central nervous system (CNS) penetration; therefore, CNS metastases cannot be well controlled. However, entrectinib is a very CNS-penetrant brain metastases-active compound, says Doebele.

Entrectinib may allow for better upfront control of existing brain metastases, and may prevent the development of brain metastases in the future.